Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle

Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of its common stock and

Investing.com reports Cabaletta Bio (CABA) shares fell about 1.6% after Q2 2026 results. Net loss was $(0.73) per share, down 30% year over year. Cash was about $225.1M, expected to fund operations only into mid-2027. The update included Phase 1/2 data and a new CMC partner, plus an SEC Form 8-K.

Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be subm

Cabaletta Bio (NASDAQ:CABA) reported positive early clinical and translational data from the first four patients in the lowest-dose cohort of preconditioning-free (PC-free) rese-cel, an investigational autologous CAR T therapy for autoimmune diseases, and manufacturing/translational results from the first two autoimmune patients treated using the Cellares Cell Shuttle platform. The company said higher doses may be needed without preconditioning and that 50% showed drug-free responses for six mon

The US Air Force plans to buy a VIP-configured B737-8 from Boeing for $250M under the 2026 NDAA, expanding its C-40 fleet. This follows a July solicitation for training services, with the contract starting November 1. The Air Force currently operates 13 C-40s, with previous MAX aircraft plans blocked. In 2025, it considered B737-9s for fleet expansion.

JPMorgan Chase (JPM) and Qatar Investment Authority agreed to a $20 billion partnership, with $15 billion allocated to global public equities and $5 billion to private market investments. This deal strengthens JPMorgan's role as a multi-asset manager for sovereign clients and aligns with its strategy of diversifying revenue streams through asset management.